



## EMMESSAR BIOTECH & NUTRITION LTD

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001  
Tel: 66356209/10/11 Fax: 66370190 Email: [enquiries@ebnl.org](mailto:enquiries@ebnl.org) Site: [www.ebnl.org](http://www.ebnl.org)  
Investors Grievance Email: [investors@ebnl.org](mailto:investors@ebnl.org) CIN No. L24110MH1992PLC065942

EBN/2017/S-2370

August 1, 2017

Dept. of Corporate Services  
The Stock Exchange, Mumbai  
1<sup>st</sup> floor, New Trading Ring, Rotunda Bldg  
Phiroze Jeebhoy Towers, Dalal Street  
Fort, Mumbai – 400 001.  
Fax No. 22723121 Email ID: [corp.relations@bseindia.com](mailto:corp.relations@bseindia.com)

Dear Sir,

Ref: Company Code No. 524768  
Sub: Outcome of the Board Meeting.

Pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015, this is to inform you that the Board of Directors of the Company, at its meeting held today at 2 pm, have approved and taken on record the Un-Audited Financial Results of the Company for the quarter ended June 30, 2017.

We are attaching herewith the following for your records.

1. Un-Audited Financial Results alongwith the Segmentwise & Revenue and Capital Employed Results.
2. Limited Review dated August 1, 2017.

The above results were reviewed by the audit committee of the Board of Directors. This is for your information and record.

We are filing the results online in .pdf and XBRL format.

Thanking you,

Yours faithfully,  
For Emmessar Biotech & Nutrition Ltd



Compliance Officer  
Attachment: As above.

EMMESSAR BIOTECH & NUTRITION LIMITED				
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2017				
Rs in Lakhs				
Particulars	Current 3 Months Ended 30.06.2017 Unaudited	Preceding 3 months ended 31.03.2017 Audited	Corresponding Qtr ended 30.06.2016 Unaudited	Previous Year Ended 31.3.2017 Audited
<b>PART I</b>				
<b>01. Income from Operations</b>				
(a) Net Sales/Income from Operations (Net of Excise Duty)	55.18	72.49	105.16	263.30
(b) Other Operating Income	0.00	0.00	0.00	0.00
<b>Total Income</b>	<b>55.18</b>	<b>72.49</b>	<b>105.16</b>	<b>263.30</b>
<b>02) Expenditure</b>				
(a) Cost of material consumed	37.86	13.23	61.82	77.81
(b) Purchase of Stock-trade	7.39	5.92	6.21	18.74
(c) Change in Inventories of Finished goods	-36.86	25.08	-71.11	-0.71
(d) Employee Benefit Expenses	9.43	10.11	9.08	38.96
(e) Depreciation & Amortisation of Assets	0.29	0.35	0.27	1.15
(f) Other Expenditure	-46.97	18.82	77.20	106.78
<b>(g) Expenditure (a to f)</b>	<b>65.08</b>	<b>73.51</b>	<b>83.47</b>	<b>242.73</b>
03) Profit / (loss) from Operations before Other Income, Interest & Exceptional items(1 - 2)	-9.90	-1.02	21.69	20.57
04) Other Income	31.35	32.74	16.20	97.53
05) Profit / (loss) before Interest and Exceptional Items (3 + 4)	21.45	31.72	37.89	118.10
06) Interest	0.00	0.00	0.00	0.00
07) Profit / (loss) after Interest but before Exceptional Items (5 - 6)	21.45	31.72	37.89	118.10
08) Exceptional Items	0.00	0.00	0.00	0.00
09) Profit / (loss) from Ordinary Activities Before Taxation (7 + 8)	21.45	31.72	37.89	118.10
10) Tax Expense (Deferred Tax)	0.00	0.06	0.00	0.06
11) Net Profit / (loss) from Ordinary Activities after Taxation (9 - 10)	21.45	31.66	37.89	118.04
12) Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00
13) Net Profit / (loss) for the period (11-12)	<b>21.45</b>	<b>31.66</b>	<b>37.89</b>	<b>118.04</b>
14) Share of profit / (loss) of associates		0.00	0.00	0.00
15) Minority Interest		0.00	0.00	0.00
16) <b>Net profit / (loss) for the period (13+14+15)</b>	<b>21.45</b>	<b>31.66</b>	<b>37.89</b>	<b>118.04</b>



17) Paid-up Equity Share Capital (Face Value of the share)	499.61 10.00	499.61 10.00	499.61 10.00	499.61 10.00
18) Reserves excluding Revaluation Reserve as per Balance Sheet of previous actg year	0.00	0.00	0.00	0.00
19) Earning per Shares	0.43	0.63	0.76	2.36
a) Basic & diluted EPS before Extraordinary items for the period, for the year to date & for the previous year (not to be annulised)				
b) Basic & diluted EPS after Extraordinary items for the period, for the year to date & for the previous year (not to be annulised)	0.43	0.63	0.76	2.36

\* The above results were reviewed by the Audit Committee of the Board of Directors.

\* The Statutory Auditors have carried out a Limited Review of the results for the quarter ended June 30, 2017

\* The above Un-Audited Results were taken on record at the meeting of the Board of Directors held on 1st August, 2017

\* During this quarter, the company has operated Healthcare & Fine Chemical segments

Mumbai  
01-Aug-17

*Ashok M. Kadakia*  
By order of the Board  
Ashok M. Kadakia  
Chairman



**EMMESSAR BIOTECH & NUTRITION LIMITED**

**Quarter ended Segment wise Revenue Results and Capital Employed**

[Rs. In Lakhs]

	Current 3 Months Ended 30.06.2017 Unaudited	Preceeding 3 months ended 31.03.2017 Audited	Corresponding Qtr ended 30.06.2016 Unaudited	Previous Year Ended 31.3.2017 Audited
1. Segment Revenue (Net Sales / Income)				
a. Healthcare	5.68	22.99	35.35	87.40
b. Fine Chemicals	49.50	49.50	69.81	175.90
c. Others	31.35	32.73	16.19	97.52
Total:	86.53	105.22	121.35	360.82
Less: Inter Segment Revenue	0	0.00	0.00	0.00
Net Sales / Income from Operations	86.53	105.22	121.35	360.82
2. Segment Results (Profit / Loss) before Tax and Interest				
a. Healthcare	3.24	13.85	20.76	52.95
b. Fine Chemicals	9.70	2.96	30.84	43.40
c. Others	31.35	34.23	16.20	97.52
Total:	44.29	51.04	67.80	193.87
Less:				
Interest	0	0.00	0.00	0.00
Other Unallocable Expenditure net off Unallocable Income	22.84	19.32	29.91	75.77
Total Profit before Tax	21.45	31.72	37.89	118.10
3. Capital Employed (Segment Assets - Segment Liabilities)				
a. Healthcare	3.62	7.51	2.21	7.51
b. Fine Chemicals	73.40	57.42	28.89	57.42
c. Others	-54.72	-20.70	13.43	-20.70
Total:	22.30	44.23	44.53	44.23

Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature.

The above results were taken on record at a meeting of the Board of Directors held on August 1, 2017

Mumbai  
01-Aug-17

*Ashok M. Kadakia*  
By order of the Board  
Ashok M. Kadakia  
Chairman



Tel. : 2200 4465, 2206 7440  
Fax : 91-22-2200 0649  
E-mail : mumbai@vsa.co.in  
Website : www.vsa.co.in

**V. Sankar Aiyar & Co.**  
CHARTERED ACCOUNTANTS  
2-C, Court Chambers  
35, New Marine Lines  
Mumbai - 400 020

**LIMITED REVIEW REPORT ON THE UNAUDITED FINANCIAL RESULTS**

**FOR THE THREE MONTHS ENDED 30<sup>TH</sup> JUNE 2017**

The Board of Directors  
Emmessar Biotech & Nutrition Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Emmessar Biotech & Nutrition Limited, for the Three months ended 30<sup>th</sup> June 2017. This statement is the responsibility of the Company's management and has been approved by the Board of Directors at its Meeting held on August 01, 2017. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Agreement and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatements.

For V. Sankar Aiyar & Co.  
Chartered Accountants  
Firm Regn. No.109208W



(V. Mohan)  
Partner  
Membership No. 17748

Place: Mumbai

Date: August 01, 2017.